期刊文献+

Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose 被引量:1

原文传递
导出
摘要 Background Next-generation sequencing has revolutionized our perspective on the gut microbiome composition,revealing the true extent of the adverse effects of antibiotics.The impact of antibiotic treatment on gut microbiota must be considered and researched to provide grounds for establishing new treatment strategies that are less devastating on commensal bacteria.This study investigates the impact on gut microbiome when a commonly used antibiotic,azithromycin is administered,as well as uncovers the benefits induced when it is used in combination with lactulose,a prebiotic known to enhance the proliferation of commensal microbes.Methods 16S rRNA gene sequencing analysis of stool samples obtained from 87 children treated with azithromycin in combination with or without lactulose have been determined.Children's gut microbial profile was established at the pre-and post-treatment stage.Results Azithromycin caused an increase in the relative abundance of opportunistic pathogens such as Streptococcus that was evident 60 days after treatment.While few days after treatment,children who also received lactulose started to show a higher relative abundance of saccharolytic bacteria such as Lactobacillus,Enterococcus,Anaerostipes,Blautia and Roseburia,providing a protective role against opportunistic pathogens.In addition,azithromycin-prebiotic combination was able to provide a phylogenetic profile more similar to the pre-treatment stage.Conclusion It is suggested that during azithromycin treatment,lactulose is able to reinstate the microbiome equilibrium much faster as it promotes saccharolytic microbes and provides a homeostatic effect that minimizes the opportunistic pathogen colonization.
出处 《World Journal of Pediatrics》 SCIE CAS CSCD 2020年第2期168-176,共9页 世界儿科杂志(英文版)
基金 This clinical study was funded by OJSC AVVA RUS,Russia.
  • 相关文献

参考文献2

二级参考文献11

  • 1Thia KT,Loftus EV,Sandborn WJ,Yang SK.An update on the epidemiology of inflammatory bowel disease in Asia[].The American journal of Gastroenterology.2008
  • 2Xavier,RJ,Podolsky,DK.Unravelling the pathogenesis of inflammatory bowel disease[].Nature.2007
  • 3Takaishi H,Matsuki T,Nakazawa A,Takada T,Kado S,Asahara T,Kamada N,Sakuraba A,Yajima T,Higuchi H,Inoue N,Ogata H,Iwao Y,Nomoto K,Tanaka R,Hibi T.Imbalance in intestinal microflora constitution could be in- volved in the pathogenesis of inflammatory bowel disease[].International Journal of Medical Microbiology.2008
  • 4Sokol H,Seksik P,Rigottier-Gois L,Lay C,Lepage P,Podglajen I,Marteau P,Doré J.Specificities of the fecal microbiota in inflammatory bowel disease[].Inflammatory Bowel Diseases.2006
  • 5Manichanh C,Rigottier-Gois L,Bonnaud E,Gloux K,Pelletier E,Frangeul L,Nalin R,Jarrin C,Chardon P,Marteau P,Roca J,Dore J.Reduced diversity of faecal microbiota in Crohn‘s disease revealed by a metagenomic approach[].Gut.2006
  • 6P. Vernia,A. Marcheggiano,R. Caprilli.Short-chain fatty acid topical treatment in distal ulcerative colitis[].Alimentary Pharmacology and Therapeutics.1995
  • 7Peng L,Li ZR,Green RS, et al.Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.[].The Journal of Nutrition.2009
  • 8Scheppach W.Effects of short chain fatty acids on gutmorphology and function[].Gut.1994
  • 9C Lay,L Rigottier-Gois,K Holmstr?m,M Rajilic,EE Vaughan,WM Vos,MD Collins,R Thiel,P Namsolleck,M Blaut,J Doré.Colonic microbiota signatures across five northern European countries[].Applied and Environmental Microbiology.2005
  • 10Segain JP,Raingeard de la Blétière D,Bourreille A,Leray V,Gervois N,Rosales C,Ferrier L,Bonnet C,Blottière HM,Galmiche JP.Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn‘s disease[].Gut.2000

共引文献34

同被引文献3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部